Learning Objectives:
1. Evaluate a noninferiority trial with regard to study design and methods.
2. Critique a noninferiority trial with regard to statistical analysis.
3. Evaluate and modify patient educational materials for oncology therapies based on results of a noninferiority trial.

Learning Objectives:
1. Formulate chemotherapeutic treatment regimens for patients with newly diagnosed glioblastoma, considering differing patient characteristics.
2. Discuss the different chemotherapeutic agents and associated toxicities of these agents that are used in treatment regimens for glioblastoma.
3. Evaluate the findings and limitations of current literature for newly diagnosed glioblastoma and translate into clinical scenarios.

Learning Objectives:
1. Describe the role of the immune system as it relates to disease pathophysiology in melanoma and the observed toxicities from agents that inhibit immune checkpoints.
2. Compare and contrast the toxicity profiles between the combination of nivolumab and ipilimumab with those seen when each is used as a single agent and discuss management strategies.
3. Formulate first-line treatment recommendations for advanced melanoma, considering unique patient characteristics.
Prostate Cancer
Rebecca Greene, Pharm.D., BCOP
Pharmacy Program Manager, Oncology
Orlando VA Medical Center
Orlando, Florida

Learning Objectives:
1. Select appropriate patients to receive docetaxel at the initiation of androgen deprivation therapy for metastatic hormone-sensitive prostate cancer.
2. Identify toxicities associated with early use of docetaxel in metastatic hormone-sensitive prostate cancer.
3. Discuss clinically relevant outcomes associated with docetaxel at the initiation of androgen deprivation therapy for metastatic hormone-sensitive prostate cancer.

Renal Cell Carcinoma
Rebecca Greene, Pharm.D., BCOP
Pharmacy Program Manager, Oncology
Orlando VA Medical Center
Orlando, Florida

Learning Objectives:
1. Describe the novel mechanism of action of nivolumab in renal cell carcinoma.
2. Evaluate the outcomes of nivolumab for previously treated patients with metastatic renal cell carcinoma.
3. Identify and formulate a plan to manage adverse events associated with nivolumab.

Blood Cancers, Bone Marrow Transplant, and Oncology Practice Management

Adult Acute Leukemias
Myke R. Green, BS Pharm, Pharm.D., BCOP
Clinical Staff Pharmacist
Banner University Medical Center—Tucson
Tucson, Arizona

Learning Objectives:
1. Evaluate salvage therapy with blinatumomab in adult patients with Philadelphia chromosome-negative precursor B-cell acute lymphoblastic leukemia (ALL).
2. Identify toxicities and supportive care in adult patients with Philadelphia chromosome-negative precursor B-cell ALL receiving blinatumomab.
3. Describe factors influencing and associated with clinical outcomes in adult patients with relapsed or refractory Philadelphia chromosome-negative precursor B-cell ALL receiving blinatumomab.
Chronic Leukemias
Karen M. Fancher, Pharm.D., BCOP
Assistant Professor of Pharmacy Practice,
Duquesne University Mylan School of Pharmacy
Clinical Pharmacy Specialist,
University of Pittsburgh Medical Center at Passavant
Pittsburgh, Pennsylvania

Learning Objectives:
1. Design and justify principles of treatment and supportive care for patients with chronic lymphocytic leukemia.
2. Evaluate the outcomes and toxicities of ofatumumab + chlorambucil compared with chlorambucil alone in patients with chronic lymphocytic leukemia.
3. Design and justify principles of treatment and supportive care for patients with chronic myelogenous leukemia.
4. Compare and contrast the relevant outcomes of a clinical trial in newly diagnosed chronic phase chronic myelogenous leukemia.

HSCT/BMT Transplant
Julianna Merten, Pharm.D., BCPS, BCOP
Clinical Pharmacy Specialist
Mayo Clinic
Rochester, Minnesota

Learning Objectives:
1. Develop a plan for ancillary and supportive therapy for patients with chronic graft versus host disease (GVHD).
2. Manage toxicities of medications used to manage chronic GVHD.
3. Devise a monitoring plan for patients with chronic GVHD.

Practice Management
Christopher A. Fausel, Pharm.D. MHA, BCOP
Clinical Manager, Oncology Pharmacy
Indiana University Simon Cancer Center
Chair,
Hoosier Oncology Group
Indianapolis, Indiana

Learning Objectives:
1. Describe the scope of issues impairing the delivery of high-quality, efficient, and cost-effective cancer care that prompted the authors to advance their proposals.
2. Describe the tripartite solution the authors prescribe to improve the current cancer care model.
3. Assess the merit of the authors’ proposals to achieve their stated intentions relative to ongoing challenges in the cancer care delivery system.
4. Articulate limitations of the authors’ proposals, with particular attention to issues related to pharmacy practice.
Learning Objectives:

1. Differentiate acute and chronic oxaliplatin-induced neuropathy in patients with colorectal cancer receiving mFOLFOX6 for curative intent.
2. Compare manifestation and evolution over time of acute oxaliplatin-induced neuropathy in patients with colorectal cancer receiving mFOLFOX6 for curative intent.
3. Design protocols for assessment and management of acute and chronic oxaliplatin-induced neuropathy in patients with colorectal cancer receiving mFOLFOX6 for curative intent.